- Jacobs selected by FUJIFILM Diosynth Biotechnologies for $1.2 billion expansion project.
- Expansion to include additional bioreactors and significant manufacturing space.
Jacobs has been chosen by FUJIFILM Diosynth Biotechnologies to manage a $1.2 billion expansion of their cell culture contract manufacturing site in Holly Springs, North Carolina. This project builds on the initial construction phase that began in 2021, with Jacobs providing engineering, procurement, and construction management services.
“This expansion of the project at Holly Springs is testament to the relationship of trust and accountability Jacobs and FUJIFILM Diosynth Biotechnologies have built,” said Jacobs Senior Vice President Koti Vadlamudi. “Together we’ll continue to leverage digital innovation and modular design so that medicines and therapies are delivered with quality, flexibility, speed and consistency—now at an even larger scale.”
The expansion will add 8 x 20,000-liter cell culture bioreactors and approximately 400,000 square feet of manufacturing space, supplementing the initially planned 8 x 20,000-liter capacity. The first phase of construction is expected to be completed by 2025, with the entire expansion scheduled for completion by 2028.
“Once complete, the site will be one of the largest, end-to-end cell culture contract manufacturing facilities in North America,” said FUJIFILM Diosynth Biotechnologies COO and Executive Vice President of Operations Kenneth Bilenberg. “Leveraging our KojoXTM philosophy, the project will significantly increase FUJIFILM Diosynth Biotechnologies’ manufacturing capacity for biologic therapeutics and medicines for patients globally. The site will provide drug substance manufacturing, automated fill-finish and assembly, packaging, and labeling services for global biopharmaceutical customers.”
Overview of outsourcing trends 
